Table 1 Prevalence of elevated triglycerides and atherogenic dyslipidemia in the general population and high-risk patient groups

General populations

 Europe [26]

> 2.2 mmol/L

23.0% (8316/36,160)

TG > 2.2 mmol/L + HDL-C < 1.0 mmol/L (treatment not specified)

6.0% (2169/36,160)

  On statin [26]

> 2.2 mmol/L

30.0% (10,848/36,160)

 USA [28, 30]

  Not on statin

≥ 2.26 mmol/L

11.9% (21.5 M/181.0 M)*

TG ≥ 2.26 mmol/L + HDL-C < 1.0 mmol/L (treatment not specified)

6.6% (13.1 M/199.1 M)*

  On statin

≥ 2.26 mmol/L

15.4% (6.0 M/38.9 M)*

High risk populations

 Primary prevention + risk factors [31]

≥ 2.3 mmol/L

20.8% (1591/7641)

Elevated TG + HDL-C < 1.0 mmol/L

9.9% (759/7641)

 With T2DM [31]

≥ 2.3 mmol/L

27.5% (562/2046)

Elevated TG + HDL-C < 1.0 mmol/L

14.9% (305/2046)

 Clinical ASCVD [29, 32]

> 1.7 mmol/L

34.7% (2938/8467)

TG > 2.0 mmol/L + HDL-C < 1.0 mmol/L in men, < 1.2 mmol/L in women

13–14%**